Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer's disease pathology.
Nicholas James AshtonWagner S BrumGuglielmo Di MolfettaAndrea L BenedetBurak ArslanErin JonatisRebecca E LanghoughKarly CodyRachael WilsonCynthia M CarlssonEugeen VanmechelenLaia Montoliu-GayaJuan Lantero-RodriguezNesrine RahmouniCécile TissotJenna StevensonStijn ServaesJoseph TherriaultTharick PascoalAlberto LleóDaniel AlcoleaJuan ForteaPedro Rosa-NetoSterling JohnsonAndreas JerominKaj BlennowHenrik ZetterbergPublished in: medRxiv : the preprint server for health sciences (2023)
These results demonstrate the high-performance of the ALZpath plasma pTau217 Simoa in identifying AD-type pathophysiology. The wider availability of high-performing assays will expedite the use of blood biomarkers in clinical settings and benefit the research community.